BSE Live
Mar 23, 16:01Prev. Close
169.75
Open Price
168.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 23, 15:57Prev. Close
170.05
Open Price
168.21
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
160.20 (2347)
| Balance Sheet of Marksans Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 12.50 | 10.00 | |
| Total Share Capital | 26.00 | 10.00 | |
| Reserves and Surplus | 52.68 | 5.43 | |
| Total Reserves and Surplus | 52.68 | 5.43 | |
| Total Shareholders Funds | 78.68 | 15.43 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 54.35 | 32.33 | |
| Deferred Tax Liabilities [Net] | 4.47 | 1.41 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 58.82 | 33.74 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 29.02 | 10.66 | |
| Trade Payables | 35.72 | 19.54 | |
| Other Current Liabilities | 4.22 | 0.68 | |
| Short Term Provisions | 2.23 | 0.64 | |
| Total Current Liabilities | 71.18 | 31.52 | |
| Total Capital And Liabilities | 232.13 | 80.69 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 101.64 | 43.33 | |
| Intangible Assets | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 101.64 | 43.33 | |
| Non-Current Investments | 0.26 | 0.01 | |
| Deferred Tax Assets [Net] | 0.26 | 0.69 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 2.10 | 0.09 | |
| Total Non-Current Assets | 104.25 | 44.11 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 48.52 | 13.97 | |
| Trade Receivables | 57.20 | 18.53 | |
| Cash And Cash Equivalents | 9.51 | 2.56 | |
| Short Term Loans And Advances | 12.64 | 1.52 | |
| OtherCurrentAssets | 0.00 | 0.00 | |
| Total Current Assets | 127.88 | 36.58 | |
| Total Assets | 232.13 | 80.69 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 0.41 | 0.00 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 21.29 | 20.41 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 0.09 | 0.12 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 44.71 | 11.24 | |
| Other Earnings | -- | -- | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | -- | -- | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | -- | |
| Non-Current Investments Unquoted Book Value | 0.26 | 0.01 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth